Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,287 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
CDC7 inhibition induces replication stress-mediated aneuploid cells with an inflammatory phenotype sensitizing tumors to immune checkpoint blockade.
Morita TY, Yu J, Kashima Y, Kamata R, Yamamoto G, Minamide T, Mashima C, Yoshiya M, Sakae Y, Yamauchi T, Hakozaki Y, Kageyama SI, Nakamura A, Lightcap E, Tanaka K, Niu H, Kannan K, Ohashi A. Morita TY, et al. Among authors: kannan k. Nat Commun. 2023 Nov 18;14(1):7490. doi: 10.1038/s41467-023-43274-3. Nat Commun. 2023. PMID: 37980406 Free PMC article.
A CDC7 inhibitor sensitizes DNA-damaging chemotherapies by suppressing homologous recombination repair to delay DNA damage recovery.
Iwai K, Nambu T, Kashima Y, Yu J, Eng K, Miyamoto K, Kakoi K, Gotou M, Takeuchi T, Kogame A, Sappal J, Murai S, Haeno H, Kageyama SI, Kurasawa O, Niu H, Kannan K, Ohashi A. Iwai K, et al. Among authors: kannan k. Sci Adv. 2021 May 21;7(21):eabf0197. doi: 10.1126/sciadv.abf0197. Print 2021 May. Sci Adv. 2021. PMID: 34020950 Free PMC article.
A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors.
Juric D, Barve M, Vaishampayan U, Roda D, Calvo A, Jañez NM, Trigo J, Greystoke A, Harvey RD, Olszanski AJ, Opyrchal M, Spira A, Thistlethwaite F, Jiménez B, Sappal JH, Kannan K, Riley J, Li C, Li C, Gregory RC, Miao H, Wang S. Juric D, et al. Among authors: kannan k. Cancer Med. 2024 Mar;13(5):10.1002/cam4.6776. doi: 10.1002/cam4.6776. Cancer Med. 2024. PMID: 38501219 Free PMC article. Clinical Trial.
Translational exposure-efficacy modeling to optimize the dose and schedule of taxanes combined with the investigational Aurora A kinase inhibitor MLN8237 (alisertib).
Huck JJ, Zhang M, Mettetal J, Chakravarty A, Venkatakrishnan K, Zhou X, Kleinfield R, Hyer ML, Kannan K, Shinde V, Dorner A, Manfredi MG, Shyu WC, Ecsedy JA. Huck JJ, et al. Among authors: kannan k. Mol Cancer Ther. 2014 Sep;13(9):2170-83. doi: 10.1158/1535-7163.MCT-14-0027. Epub 2014 Jun 30. Mol Cancer Ther. 2014. PMID: 24980948
A phase Ib trial of mivavotinib (TAK-659), a dual SYK/FLT3 inhibitor, in patients with relapsed/refractory acute myeloid leukemia.
Pratz KW, Kaplan J, Levy M, Bixby D, Burke PW, Erba H, Wise-Draper TM, Roboz GJ, Papadantonakis N, Rajkhowa T, Hernandez D, Dobler I, Gregory RC, Li C, Wang S, Stumpo K, Kannan K, Miao H, Levis M. Pratz KW, et al. Among authors: kannan k. Haematologica. 2023 Mar 1;108(3):705-716. doi: 10.3324/haematol.2022.281216. Haematologica. 2023. PMID: 36226495 Free PMC article. Clinical Trial.
The Maternal and Infant Environmental Health Riskscape study of perinatal disparities in greater Houston: rationale, study design and participant profiles.
Symanski E, Whitworth KW, Mendez-Figueroa H, Aagaard KM, Moussa I, Alvarez J, Chardon Fabian A, Kannan K, Walker CL, Coarfa C, Suter MA, Salihu HM. Symanski E, et al. Among authors: kannan k. Front Reprod Health. 2024 Apr 22;6:1304717. doi: 10.3389/frph.2024.1304717. eCollection 2024. Front Reprod Health. 2024. PMID: 38712340 Free PMC article.
1,287 results